ARPA Bio

How does ARPA Bio's therapeutic and diagnostic strategy differentiate from earlier, clinically approved antibodies ?

 

ARPA Bio targets early seeds of pathological species (left) during the long, insiduous phase of the disease (estimated 10-20 years before clinical manifestation). This unique strategy enables, for the first time, targeting the root cause and prior to the accumulation of neurotoxic oligomers, such as achieved with currently available and FDA approved immuno-therapies for AD (right).

ARPA's antibody molecules do not bind non-toxic monomers but rather highly specific seeds that gradually appear during the time course of amyloid-beta aggregation leading to the accumulation of neurotoxic oligomers, as shown by the dotblot screening. Conventional anti-amyloid beta antibodies, (6E10 or 4G8), do not distinguish between soluble monomers (t= 0) and neurotoxic oligomers (t=4-20hrs), wherease ARPA's antibodies only bind to highly specific (proprietatry) epitopes, that emerge during the early aggregation process. ARPA Bio unique strategy enables targeting of several, different (proprietary) epitopes, which have been shown to be highly relevant during the early, pathological process of amyloid-beta misfolding.